Yoav Avidar

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Despite resection and adjuvant therapy, the 5-year survival for patients with Glioblastoma multiforme (GBM) is less than 10%. This poor outcome is largely attributed to rapid tumor growth and early dispersal of cells, factors that contribute to a high recurrence rate and poor prognosis. An understanding of the cellular and molecular machinery that drive(More)
  • 1